Metagenomi Therapeutics (MGX) EBIT Margin (2023 - 2026)
Metagenomi Therapeutics' EBIT Margin came in at -1970.11% for Q1 2026, down 1296.01 percentage points from -674.10% a year earlier and down 1347.07 percentage points from the prior quarter.
Metagenomi Therapeutics (MGX) EBIT Margin (2023 - 2026) Analysis & Trends
Over the trailing twelve months to Mar 31, 2026, Metagenomi Therapeutics reported EBIT Margin of -415.48%, down 221.74 percentage points year-over-year; for FY2025, it was -380.85%, down 210.85 percentage points from FY2024.
- Going back by year, EBIT Margin was -170.00% in FY2024 (+5.38 pp) and -175.38% in FY2023.
- The Q1 2026 figure represents the lowest quarterly EBIT Margin in data going back to Q1 2023.
- Year-over-year, EBIT Margin has declined for seven consecutive quarters, with an average year-over-year change of -292.60 percentage points over the last eight quarters.
- The fastest year-over-year change in EBIT Margin over five years came in Q2 2024 (a gain of 74.16 percentage points), and the weakest in Q1 2026 (a drop of 1296.01 percentage points).
- Business Quant data shows MGX's EBIT Margin at -623.04% (Q4 2025), -263.76% (Q3 2025) and -246.53% (Q2 2025) in the three quarters before Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | 28.37% |
| 10 | Metagenomi Therapeutics | 30.49 Mn | -575.25 Mn | - | - |
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,970.11% |
| Dec 31, 2025 | -623.04% |
| Sep 30, 2025 | -263.76% |
| Jun 30, 2025 | -246.53% |
| Mar 31, 2025 | -674.10% |
| Dec 31, 2024 | -214.51% |
| Sep 30, 2024 | -194.40% |
| Jun 30, 2024 | -84.28% |
| Mar 31, 2024 | -260.17% |
| Dec 31, 2023 | -162.88% |
| Sep 30, 2023 | -181.15% |
| Jun 30, 2023 | -158.45% |
| Mar 31, 2023 | -207.21% |
Metagenomi Therapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=MGX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "MGX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=MGX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();